Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-NHL 2013
NCT03206671Phase 3Active, not recruiting
- Sponsor
- Universitätsklinikum Münster
- Start
- Aug 2017
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of rituximab in mature B-cell non-Hodgkin lymphoma, Burkitt lymphoma (BL), Burkitt leukemia and 1 more (5 arms), sponsored by Universitätsklinikum Münster. Primary endpoints: Event-free survival up to 7 years and Immune reconstitution rate at 12 months. Started Aug 2017; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
mature B-cell non-Hodgkin lymphomaBurkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03206671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206671.